6,678 trials
Idiopathic Parkinson's Disease
Primary: Change From Baseline to the End of the Maintenance Period in the Score of the Apathy Evaluation Scale (AS) Rated by the Patient — -4.4; -4.6; -4.9 scores on a scale…
Alpha1-proteinase Inhibitor Deficiency · Emphysema
Primary: Annual Rate of Change in Lung Density — -1.50; -2.12; -1.45; -2.19 g/L per year — p=0.029
Autosomal Dominant Polycystic Kidney Disease
Primary: Primary Efficacy Analysis of Total Kidney Volume (mITT Set, Multiple Imputation) — 230.1; 300.8 mL
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Primary: Agreement Between POCone and UBiT-IR300. — 0.990; 0.995; 0.990
Kidney Failure
Primary: The Primary Outcome Measure Was the Incidence of Post-biopsy Bleeding Complications. — 25; 11 participants — p=0.01
Cathartics · Mobile Applications
Primary: Bowel Preparation Was Evaluated Using the Harefield Cleansing Scale (HCS). The Scale Was the Primary Outcome Measure — 17.05; 16.52 units on a scale
Overweight · Obese · Prehypertension
Primary: Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time) — 0.253; -0.804 mu/L/min
Hepatitis B
Primary: Number of Subjects Seroprotected for Anti- Hepatitis B Surface Antigen (Anti-HBs) Antibodies — 285; 155 Participants
Healthy
Primary: Change in Energy Intake Measured Before Treatment and at the End of Treatment. — -167 kcal/d — p=0.001
Vaginal Surgery
Primary: Pain at Hour 4 — 4.2; 4.1 units on a scale — p=0.82
Infertility
Primary: Pregnancy Success Rate — 75; 25 percentage of participants
Chronic Hepatitis C · Genotype 1
Primary: Treatment Duration Compliance Rate — 85.4; 83.8 Percentage of compliance — p=0.4864
HIV Infections
Primary: Change From Baseline in CD4 Count at 48 Weeks — 192; 205 cells/uL
Gout
Primary: Resolution of the Acute Gout Attack — 15.4; 13.4 days — p=0.5
Nasal Obstruction Present Finding
Primary: Effectiveness of Oxymetazoline in the Treatment of Rhinitis With Persistent Nasal Obstruction — 1.38; 1.67 units on a scale